Effectiveness and feasibility of telerehabilitation in patients with COVID-19: a protocol for a systematic review and meta-analysis

• Published in: BMJ open 2022-01, Vol.12 (1), p.e058932-e058932
• Main Authors: Seid, Abubeker Alebachew, Aychiluhm, Setognal Birara, Mohammed, Ahmed Adem
• Format: Article
• Language: English
• Subjects: Bias; Chronic obstructive pulmonary disease; Coronaviruses; Cost analysis; COVID-19; Dyspnea; Exercise; Feasibility Studies; Humans; Internet; Intervention; Meta-analysis; Meta-Analysis as Topic; Patients; Physical fitness; Physical therapy; Quality of Life; Rehabilitation; Rehabilitation Medicine; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Sleep Quality; Software; Sports training; Strength training; Systematic review; Systematic Reviews as Topic; Telemedicine; Telerehabilitation
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2021-058932

IntroductionRespiratory rehabilitation is the use of exercise, education, and behavioural interventions to alleviate symptoms and improve quality of life. Recent studies highlight that respiratory rehabilitation is effective and safe for patients with COVID-19. We aim to evaluate the effectiveness and feasibility of respiratory telerehabilitation on patients infected with COVID-19 by conducting a systematic review and meta-analysis.Methods and analysisPubMed, Web of Science, Science Direct, Physiotherapy Evidence Database, Google Scholar and Cochrane Library databases will be searched from inception to the end of November 2021. Randomised controlled trials investigating the effectiveness of telerehabilitation in the management of COVID-19 will be included. The primary outcomes will be functional capacity, cardiopulmonary exercise tests and quality of life. Secondary outcomes will include anxiety/depression level, sleep quality, mortality rate, completion rate, reason for withdrawal, adverse events, service satisfaction, cost-effectiveness and other potential factors. Two reviewers will independently screen and extract data and perform quality assessment of included studies. The Cochrane risk of bias tool will be used to assess risk of bias. Review Manager V.5.4 (Cochrane Collaboration) software will be used for statistical analysis. Heterogeneity will be analysed using I² statistics. Mean difference or standardised mean difference with 95% CI and p value will be used to calculate treatment effect for outcome variables.Ethics and disseminationEthical approval is not required because this systematic review and meta-analysis is based on previously published data. Final result will be published in peer-reviewed journal and presented at relevant conferences and events.PROSPERO registration numberCRD42021287975.